What Is Bioresonance? Pseudoscience.

Persistent fatigue, pain, bloating or headaches can shrink a life while leaving no tidy answer on a laboratory report. Allergic symptoms may seem to follow food one week and ignore it the next. Appointments are brief, specialist waiting lists are long, and being told that routine tests are normal does not make a person feel normal. That gap between suffering and explanation is where bioresonance finds its customer. It offers a single cause, displayed on a screen, followed immediately by something to buy. The suffering is real. The claim that a frequency scan can “diagnose” its hidden cause and “correct” the body is pseudoscience.

Bioresonance is a family of pseudoscientific “diagnostic” and “treatment” practices rather than one standardized procedure. A typical claim says that cells, organs, foods, pathogens or toxins possess characteristic electromagnetic frequencies. A device is said to “detect” disturbed frequencies through electrodes, a hand cradle, a probe or even a submitted hair sample. Software then labels the pattern an intolerance, deficiency, infection or imbalance. What promoters call “treatment” may involve sending a supposedly “corrected” or inverted frequency back to the body. The UK advertising regulator says it has yet to see evidence that bioresonance devices can diagnose existing or future medical conditions, or prevent or treat disease [1]. The machine may produce numbers. The unsupported medical meaning is supplied by the seller.

The modern method grew from electrodermal testing and was developed in the 1970s. In one common version, an electrode supposedly receives bodily oscillations, a machine supposedly separates “healthy” signals from “pathological” ones, and another electrode allegedly returns the “corrected” pattern. Test substances can be placed in a circuit or represented in software. A systematic review by the Ludwig Boltzmann Institute for Health Technology Assessment found only hypothetical explanations for the proposed physical and physiological interactions [2]. The apparatus is thus promoted as “finding” disease, choosing a “treatment” and checking whether it worked before its sellers have shown that it can recognise the disease in the first place. It is an efficient workflow for sales, if not for diagnosis.

Human biology does involve electricity. Nerves transmit electrical impulses, the heart produces activity recorded by an electrocardiogram, and charged particles move across cell membranes. Those facts do not validate every device that includes the words energy or frequency. A useful medical signal must be identified, measured reliably and linked to a specific condition through evidence. Some electrodermal devices measure skin conductance, meaning how easily a small electrical current passes across the skin. That value is influenced strongly by sweat gland activity and requires careful control of electrodes, recording conditions and artefacts [3]. It is not a barcode for wheat intolerance or Lyme disease.

The vocabulary helps the claim travel farther than the evidence. Resonance and electromagnetic fields are real physical concepts. Information is real too, though it becomes unusually accommodating when marketers use it without specifying a measurable signal, its strength, its units or the biological pathway that carries it. Physician and complementary medicine researcher Edzard Ernst used bioresonance as a case study in how scientific language can obscure the absence of a testable explanation [4]. Borrowing the language of physics does not turn an invented diagnosis into biophysics. It gives the sales script better scenery while the validation work remains missing.

A diagnostic device must do more than produce changing numbers. It must distinguish people who have a condition from people who do not, and it should give comparable results when the relevant circumstances are repeated. Researchers test this by blinding operators to what is being measured and comparing the device with an accepted reference method. Blinding matters because expectations and subtle cues can otherwise shape a result. So can the pressure used with a probe. A colourful report generated after an unblinded consultation may feel personal. Personalization is not the same property as accuracy.

One revealing experiment examined the Vega test, an electrodermal method closely related to bioresonance. Researchers recruited 30 volunteers, half of whom had previously tested positive by skin prick testing for allergy to cat dander or house dust mite. Experienced operators completed more than 1,500 measurements without knowing the participants’ allergy status or the substances in the circuit. The electrodermal results did not correlate with skin prick tests, distinguish allergic from non-allergic volunteers, or produce a consistently correct diagnosis for any participant [5]. When the clues were removed, the signal lost its alleged meaning.

A second double-blind study included 72 people with respiratory allergies and 28 healthy volunteers. Sealed vials containing allergens, histamine, immunoglobulins or saline were tested in duplicate. The readings varied widely, regardless of the person’s allergy status and regardless of what the vial contained. The device could not distinguish allergens from the negative control [6]. This is a direct challenge to the central sales proposition. If a method claims that a substance produces a recognizable response, it must identify that substance more reliably than it identifies saline.

These studies address specific diagnostic promises rather than every possible biological effect of every electromagnetic field. For the tasks tested, the devices failed to do what promoters claimed. A genuinely new diagnostic technology would need a defined signal, a reproducible protocol, blinded comparisons against a suitable reference standard and results from independent groups. Bioresonance marketing skips from the broad fact that bodies have electrical properties to the very specific claim that a proprietary machine can “diagnose” hundreds of unrelated problems. Those missing steps are not a minor research gap. They are the difference between a medical test and pseudoscientific theatre.

The “treatment” claims also fail where a useful device should succeed. The 2009 health technology assessment found a small and heterogeneous evidence base. In hay fever, bioresonance diagnosis matched conventional allergy assessment only 22 percent of the time, and treatment was no better than placebo on objective nasal tests. In a double-blind trial involving children with atopic dermatitis, symptoms improved in both the active and sham groups, with no significant difference between them. Evidence concerning gastrointestinal complaints, rheumatic disease and back pain was judged low in strength or difficult to generalize [2]. A machine cannot claim the natural rise and fall of symptoms as proof that it “corrected” a frequency.

Small positive studies and satisfied customers can still be found. Neither settles the issue. A study without a credible sham procedure cannot separate the device from symptom fluctuation, attention, expectation or concurrent changes in diet and medication. A case series chosen by practitioners cannot reveal how many people failed to improve or left. Manufacturer involvement also matters when proprietary software, settings and devices are under evaluation. The relevant comparison asks whether people assigned to genuine bioresonance do better than comparable people receiving a convincing sham, by outcomes chosen before the study begins.

There are many honest reasons for improvement after an ineffective intervention. Symptoms fluctuate. People often seek help when they are at their worst, so some improvement would have followed anyway. A long appointment can provide attention and a coherent story after months of uncertainty. A person may sleep more or begin pacing activity at the same time. Expectation can change pain and other subjective symptoms. These experiences deserve respect. They do not validate the pseudoscientific claim that a machine “detected” a parasite, “corrected” an organ frequency or “neutralized” an allergen. Comfort belongs to the person; the machine does not get to invoice for the biology it failed to demonstrate.

Food reactions provide an especially fertile market because allergy and intolerance are easily confused. An immediate food allergy often involves immunoglobulin E, or IgE, an antibody that can trigger hives, swelling, wheezing or anaphylaxis. Diagnosis starts with a detailed clinical history and may use targeted skin prick or specific IgE blood testing. Sometimes a supervised food challenge is needed. The British Society for Allergy and Clinical Immunology states that bioresonance and electrodermal methods are not valid diagnostic tests for any type of food allergy [7]. NICE likewise advises against Vega testing and hair analysis when assessing food allergy [8].

The commercial test can appear easier because it promises breadth without the inconvenience of biological plausibility. In April 2026, the Advertising Standards Authority upheld a complaint about a bioresonance hair test advertised as assessing reactions to 1,500 food and non-food items. The advertising also claimed insights into inflammation, sleep hormones, skin health and hunger-related hormones. The company described the service as complementary information, yet the regulator concluded that consumers would understand it as a reliable assessment of bodily reactions. No evidence was supplied to substantiate those claims [9]. A few strands of hair had been assigned more diagnostic responsibilities than a hospital laboratory, with rather less validation.

Breadth is commercially useful. Symptoms such as fatigue, pain, itching and digestive discomfort occur in many conditions, and they also occur without one readily identifiable disease. A system that labels them “hidden sensitivities” or “energetic stressors” can nearly always “find” something. The result appears to resolve uncertainty while creating fresh categories of concern. A long list feels comprehensive because it contains many entries. Statistically, a test that searches widely without demonstrated accuracy simply creates more opportunities to be wrong.

Some systems close the commercial loop between “finding” a problem and selling its supposed answer. In a 2023 warning letter, the US Food and Drug Administration described one galvanic skin response device whose proprietary software compared readings with virtual items representing diseases, allergens and other stressors. A subsequent scan could select supposed balancers from a library that included supplements, essential oils, homeopathic products and items from more than 250 wellness companies. The FDA said the disease and treatment uses exceeded the device’s cleared purpose, which was measuring galvanic skin response, and documented missing validation for the virtual items [10]. The same unvalidated system can therefore invent the “problem,” recommend the merchandise and later pronounce the purchase successful. Even the shopping aisle has acquired a lab coat.

Repeat “treatment” can extend the transaction. A 2019 ASA ruling recorded advertising that claimed a scanner could “find” harmful pathogens, “diagnose” conditions ranging from fatigue to Crohn’s disease, and then “treat” the detected frequencies. The advertisements included a testimonial describing a major diet change followed by “treatment” sessions. The regulator found that the submitted evidence did not support the diagnostic or treatment claims and warned that promotion involving serious conditions could discourage essential care [11]. A first scan can therefore generate both the problem and the reason to book the next scan.

A false positive is not harmless just because no needle entered the skin. Someone told that many ordinary foods are harmful may reorganize meals, social life and family routines around a “diagnosis” that was never established. Every later symptom can be read as proof of imperfect avoidance. If the list changes on retesting, the inconsistency can be sold as “progress,” a new “imbalance” or evidence that further “correction” is needed. Improvement confirms the machine, persistence sells another session, and deterioration becomes an adjustment. This is how an invalid test protects its income from its own mistakes.

Unnecessary restriction can worsen health. The Australasian Society of Clinical Immunology and Allergy warns that unscientific allergy tests can lead to misdiagnosis, ineffective treatment and dietary restrictions that cause nutritional problems, including growth concerns in children [12]. The NHS similarly advises against home intolerance tests because they may recommend avoiding multiple foods, and it urges people to seek medical or dietetic advice before cutting foods from a diet [13]. For someone already fatigued or losing weight, a needlessly narrow diet can compound the original problem while providing the seller with evidence that the body is undergoing an adjustment.

False reassurance creates a different route to harm. A machine may fail to identify a true allergy, or may attach a confident alternative label to symptoms that require investigation. Pain has many causes, from injury and inflammatory disease to cancer. Fatigue can accompany anaemia, endocrine illness, infection or sleep disorders, among many other causes. No single symptom proves one of those diagnoses, but that is precisely why a universal frequency scan is unsafe as a substitute. Time spent paying to “correct” an invented imbalance can delay the history, examination and targeted tests that might reveal a treatable condition. The absence of needles does not make lost diagnostic time reversible.

The financial cost rarely ends with the advertised test price. There may be consultations, repeat scans and sessions, followed by supplements or replacement foods. Travel and time away from work add to the bill. The larger loss is opportunity: money and energy are finite, especially during chronic illness. A person can become trapped in a sequence where every disappointing result prompts another purchase because the original “diagnosis” came from the same unvalidated system that now claims to judge recovery.

A practical way to assess any bioresonance offer is to ask for precision. What physical quantity does the device measure, in what units, and how is a disease encoded in it? Which independent blinded study shows that the machine distinguishes people with that disease from appropriate controls? What are its false positive and false negative rates? Was the treatment compared with a convincing sham? A conformity mark or clearance for measuring skin response does not validate every diagnosis later attached by software, a point made repeatedly in regulator decisions [1] [10]. Testimonials cannot supply the missing denominator.

People considering a scan deserve to have their symptoms taken seriously. Recurrent reactions after food require a careful history, and possible severe allergy needs qualified medical assessment. Persistent fatigue, pain or unexplained weight change warrants a clinician who can review timing, medication and relevant examinations, then choose tests that answer a defined question. A dietitian can help assess suspected intolerance without creating nutritional gaps. Seeking a second medical opinion is reasonable when an explanation remains unsatisfactory. Buying an answer from a machine does not make that answer more complete.

Bioresonance is pseudoscience presented as instrumentation. It turns uncertainty into a visible performance of electrodes, fluctuating readings, technical labels and a personalised report, but its central promises have failed when operators were blinded and proper controls were introduced. A device that claims to “find” hidden problems can generate the “diagnosis,” sell the matching “correction” and use its own next scan to declare success. The machine has appointed itself both sales department and medical referee. That closed commercial loop can impose unnecessary diets, drain money and divert someone from proper allergy testing or investigation of persistent pain, fatigue or weight loss. It can delay diagnosis while a real condition progresses and time-sensitive treatment becomes less likely to work. If the missed illness is serious, the available options may narrow, contributing to avoidable disability or death. People with real symptoms deserve careful assessment and honest uncertainty, not a machine that sells and grades its own answer.